References
[1] Pui C H, Pei D, Campana D, et al. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia, 2014,28(12):2336-2343.
[2] Linda Olsson B J. Ikaros and leukaemia. Br J Haematol, 2015,169(4):479-491.
[3] Stanulla M, Cave H, Moorman A V. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?. Blood, 2020,135(4):252-260.
[4] Cui L, Li Z G, Chai Y H, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China. Am J Hematol, 2018,93(7):913-920.
[5] Li-Xin Wu J Z Q Y. High frequency of IKZF1 deletions in Chinese adult patients with acute lymphoblastic leukemia detected by multiplex realtime quantitative PCR. Clinical and Diagnostic Pathology, 2017,1(2):1-7.
[6] Wang Y, Zeng H M, Zhang L P. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol. Ital J Pediatr, 2018,44(1):94.
[7] Xue Y J, Cheng Y F, Lu A D, et al. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era. Biol Blood Marrow Transplant, 2019,25(8):1611-1620.
[8] Winick N, Devidas M, Chen S, et al. Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group. J Clin Oncol, 2017,35(22):2527-2534.
[9] Payne M A. Zinc finger structure-function in Ikaros Marvin A Payne. World J Biol Chem, 2011,2(6):161-166.
[10] Mullighan C G, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med, 2009,360(5):470-480.
[11] Iacobucci I, Mullighan C G. Genetic Basis of Acute Lymphoblastic Leukemia. J Clin Oncol, 2017,35(9):975-983.
[12] Mullighan C G, Miller C B, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature, 2008,453(7191):110-114.
[13] van der Veer A, Zaliova M, Mottadelli F, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood, 2014,123(11):1691-1698.
[14] Mullighan C G. The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program, 2012,2012:389-396.
[15] Dorge P, Meissner B, Zimmermann M, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica, 2013,98(3):428-432.
[16] Enshaei A, Schwab C J, Konn Z J, et al. Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor. Leukemia, 2013,27(11):2256-2259.
[17] Vairy S, Tran T H. IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly. Blood Rev, 2020,44:100677.
[18] Caye A, Beldjord K, Mass-Malo K, et al. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica, 2013,98(4):597-601.
[19] Venn N C, van der Velden V H, de Bie M, et al. Highly sensitive MRD tests for ALL based on the IKZF1 Delta3-6 microdeletion. Leukemia, 2012,26(6):1414-1416.
[20] Olsson L, Castor A, Behrendtz M, et al. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia, 2014,28(2):302-310.
[21] Olsson L, Ivanov O I, Noren-Nystrom U, et al. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013. Br J Haematol, 2015,170(6):847-858.
[22] van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood, 2013,122(15):2622-2629.
[23] Asai D, Imamura T, Suenobu S, et al. IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan. Cancer Med, 2013,2(3):412-419.
[24] Palmi C, Valsecchi M G, Longinotti G, et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?. Haematologica, 2013,98(8):1226-1231.
[25] Volejnikova J, Mejstrikova E, Dorge P, et al. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia. Pediatr Blood Cancer, 2013,60(3):420-427.
[26] Lilljebjorn H, Henningsson R, Hyrenius-Wittsten A, et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun, 2016,7:11790.
[27] Slayton W B, Schultz K R, Kairalla J A, et al. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622. J Clin Oncol, 2018,36(22):2306-2314.